Abstract:Zhihong Liu, 1, 2, &ast Xiaofang Liang, 1, &ast Yu Zhang, 1 Wenbo Deng, 1 Yulin Wang, 3 Zhangping Lu, 2 Qianqian Liu, 2 Lianhua Wei 2 1 School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou, Gansu, People's Republic of China; 2 Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, Gansu, People's Republic of China; 3 Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lianhua Wei, Email The development of antibiotic resistance complicates the treatment of infectious diseases and is a global public health threat. However, drug repurposing can address this resistance issue and reduce research and development costs. Niclosamide is a salicylanilide compound approved by the Food and Drug Administration (FDA), and it has been used clinically for treating parasitic infections for many years. Recent studies have shown that niclosamide can inhibit bacterial and fungus activity by affecting the quorum sensing system, biofilm formation, cell membrane potential, and other mechanisms. Here, we discuss recent advances in the antimicrobial applications of niclosamide and its derivatives to provide new perspectives in treating infectious diseases. Keywords: antimicrobial resistance, multi-drug resistance, niclosamide, a derivative, drug repurposing Antibiotics have been used to treat bacterial infections for over 70 years and have been the most important class of drugs since the twentieth century. 1 However, excessive or inappropriate use of antibiotics has led to the emergence of antimicrobial resistance (AMR) and the production of multidrug-resistant (MDR) bacteria in the clinic, in animals, and even in the environment. 2 Experts estimate that AMR could force 24 million people into extreme poverty by 2030 and that MDR bacterial infections could cause 10 million deaths per year worldwide by 2050. 3 The search for new antibiotics for clinical use is becoming increasingly challenging due to the significant costs associated with drug development and the rapid emergence of drug resistance. 4 Drug repurposing is a creative strategy to address this problem. This strategy has been successfully applied to the discovery of potential treatments for a wide range of diseases, including infectious diseases. In recent years, it has been shown that, among non-antimicrobial drugs, auranofin 5 and ebselen 6 are active against many kinds of bacteria by inhibiting thioredoxin reductase (TrxR), while NIC kills microorganisms by inhibiting mechanisms such as quorum sensing systems and biofilm formation. It has attracted wide attention due to NIC's strong antibacterial activity, inhibit many kinds of bacteria, and the fact that it is not easy to develop drug resistance. NIC, a clinical antiparasitic drug approved by the FDA in 1982, works as a hydrogen ionophore that plays a role. NIC inhibits adenosine triphosphate (ATP) production through oxidative phosphorylation and uncoupling of electron transfer, leading to parasite death. 7 Over the past decades, evidence has shown that NIC can also act on other targets, such as the Wnt/β-catenin, mTOR, and JAK/STAT3 signaling pathways. 8 These pathways play an essential role in developing and progressing many diseases. The versatility of NIC has been increasingly demonstrated, while its potential in treating infectious diseases has been progressively discovered. In this paper, by searching for relevant literature in globally recognized databases such as PubMed, Web of Science, and Google Scholar. For the first time, the antibacterial and antifungal activities and mechanisms of action of NIC and its derivatives are reviewed. In addition, a brief summary of the application of NIC in other medical fields was provided. Finally, the shortcomings and perspectives of NIC and its derivatives are discussed. New ideas for the pharmaceutical reuse of NIC are provided. NIC, also known as Bayluscide, is an odorless, water-insoluble, yellowish-white crystalline powder. In the late 1950s, Bayer first discovered through screening that NIC could control Schistosoma mansoni transmission and developed and marketed it as a molluscicide. 9 In 1960, Bayer scientists discovered that it also played an essential role in controlling parasitic infections in humans. In 1962, it was marketed for human use under the trade name Yomesan. 10 The FDA added NIC to the World Health Organization (WHO) list of essential drugs in 1982. 11 Structurally, NIC belongs to a large group of lipophilic, weakly acidic molecules called salicyl -Abstract Truncated-

Pentamidine Ninety Years on: the Development and Applications of Pentamidine and its Analogs.

Discovery of 3-Cinnamamido-n-substituted Benzamides As Potential Antimalarial Agents

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint

Pentamidine Inhibits Prostate Cancer Progression Via Selectively Inducing Mitochondrial DNA Depletion and Dysfunction

Pentostatin Biosynthesis Pathway Elucidation and Its Application

Abstract 5604: Modulating DNA repair through endo-exonuclease inhibition: a new therapeutic paradigm in oncology

Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects

Repositioning Antimicrobial Agent Pentamidine As a Disruptor of the Lateral Interactions of Transmembrane Domain 5 of EBV Latent Membrane Protein 1

Investigation of the Anti-Plasmodial Properties of N-2-Oxo Pyrrolidine Pentanamide-Based Sulfonamides: Experimental and Theoretical Approach

Enhancing the Intrinsic Antiplasmodial Activity and Improving the Stability and Selectivity of a Tunable Peptide Scaffold Derived from Human Platelet Factor 4

1,2,4,5‐Tetraoxane derivatives/hybrids as potent antimalarial endoperoxides: Chronological advancements, structure−activity relationship (SAR) studies and future perspectives

Poly-basic peptides and polymers as new drug candidate against Plasmodium falciparum

Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination With Combat Multidrug-Resistant Gram-Negative Bacteria

The past, present and future of anti-malarial medicines

Hybrid Peptide-Alkoxyamine Drugs: A Strategy for the Development of a New Family of Antiplasmodial Drugs

Poly-basic peptides and polymers as new drug candidates against Plasmodium falciparum

Pyridine and Pyrimidine hybrids as privileged scaffolds in antimalarial drug discovery: A recent development

Novel Dipeptide Inhibitors of PfPNP: In‐silico Identification of Promising New Antimalarials

Chemical synthesis and enzymatic late-stage diversification of novel pantothenate analogues with antiplasmodial activity